Updates are available Correction dated 2025-03-03
Click to view Correction: https://doi.org/10.1038/s41572-025-00605-6
-
Authors
Akbarialiabad, Hossein https://orcid.org/0000-0003-2018-6378
Schmidt, Enno https://orcid.org/0000-0002-1206-8913
Patsatsi, Aikaterini https://orcid.org/0000-0001-9616-2001
Lim, Yen Loo https://orcid.org/0000-0002-1439-4106
Mosam, Anisa https://orcid.org/0000-0003-2942-6542
Tasanen, Kaisa https://orcid.org/0000-0001-8056-5949
Yamagami, Jun https://orcid.org/0000-0003-2611-6127
Daneshpazhooh, Maryam https://orcid.org/0000-0003-1020-8895
De, Dipankar https://orcid.org/0000-0002-4752-7155
Cardones, Adela Rambi G. https://orcid.org/0000-0001-7489-2046
Joly, Pascal https://orcid.org/0000-0002-8079-5004
Murrell, Dedee F. https://orcid.org/0000-0003-2971-0199
- License Information
-
More Information
Article History
Accepted: 14 January 2025
First Online: 20 February 2025
Change Date: 3 March 2025
Change Type: Correction
Change Details: A Correction to this paper has been published:
Change Details: https://doi.org/10.1038/s41572-025-00605-6
Competing interests
: H.A. is funded by the Australasian Blistering Diseases Foundation (ABDF). E.S. has a scientific cooperation with Euroimmun and holds patents with them that are not related to BP. E.S. also has scientific cooperations with Biotest, ArgenX, Fresenius Medical Care, AstraZeneca, Dompe and Sanofi, and has received honoraria from ArgenX, Fresenius Medical Care, Sanofi, Leo, Chugai and Almirall. A.P. has served as an investigator, advisory board member and speaker for AbbVie, Amgen, ArgenX, AstraZeneca, Jannsen, GenesisPharma SA, GSK, Leo, Νοvartis, Pfizer, Sanofi, Lilly and UCB. Y.L.L. is Secretary-General for the World Congress of Dermatology (WCD) 2023 in Singapore and a member of the Scientific Program Committee for the WCD2023, ILDS. She is also on the ad hoc advisory board for Sanofi at WCD2023 (honorarium paid to National Skin Centre, Singapore.). K.T. received an educational grant from Novartis and honoraria from Takeda. J.Y. is a consultant for Zenyaku Kogyo and Ono Pharma. D.D. is secretary of the International Pemphigus and Pemphigoid Conference, Chandigarh (2024). He is investigator for ArgenX (Pemphigus trial, now completed). A.R.G.C. is an author for UpToDate (with honorarium) and site principal investigator for Pfizer and Daiichi Sankyo, both for phase II studies related to lupus. She will be paid an honorarium by Elsevier for a review (DRESS syndrome). She is also secretary-treasurer of the Medical Dermatology Society, on the board of directors for the Society for Dermatology Hospitalists and is a Member of the Scientific Committee for the Society for Investigative Dermatology. P.J. is consultant for Amgen, ArgenX, AstraZeneca, Thermofisher, Sanofi, Akari, Janssen, Novartis, Servier, Chugai, Kezar Life Science, Regeneron, UCB, Principabio, Zenyaku Kogyo, Dualyx, Amgen and JJP Biologics. D.F.M. is an author for UptoDate for BP, has scientific cooperations and advisory roles in the field of eczema with Sanofi, AbbVie, Arena, Attovia, Incyte, Leo, Lilly, Galderma, Dermira, Pfizer, BMS, Kineska, Fujisawa, Novartis and Evelo. In the area of blistering diseases, she has scientific cooperations and advisory roles with ArgenX, Sanofi Regeneron, Principia, Janssen, Lilly, Ono, Almirall, RAPT and Roche. She is creator of the ABQOL/TABQOL and co-creator of the BPDAI. A.M. and M.D. declare no competing interests.
